Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05113160 · ClinicalTrials.gov registry record · NA

Conversation Group Treatment for Aphasia: Does it Work?

A NA study of Aphasia, Acquired, sponsored by Boston University Charles River Campus.

Active
Registry status
NA
Development phase
162
Enrollment target
3
Study locations

NCT05113160: Active NA study of Aphasia, Acquired, sponsored by Boston University Charles River Campus.

NCT05113160 is a NA study of Aphasia, Acquired that is active but no longer recruiting, run by Boston University Charles River Campus. The registered enrollment target is 162 participants, above the 92-participant average among 8 other Aphasia, Acquired trials with a reported enrollment target (76% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05113160, a NA study of Aphasia, Acquired, is active but no longer recruiting, sponsored by Boston University Charles River Campus.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
162 participants
Enrollment target
3
Study locations

Study Summary

The proposed research will test the efficacy of group conversation treatment for people with aphasia and explore whether the effects of treatment differ as a result of the following factors: 1. Group size: Do large groups of 6-8 people with aphasia or dyads of 2 people with aphasia demonstrate different levels of improvement with this treatment? 2. Group composition: Do effects of conversation group treatment differ if the groups include members with similar or different types of aphasia? 3. Aphasia severity: Do effects of conversation group treatment differ if the individuals within the group have mild-moderate or moderate-severe profiles of aphasia? Treatment sessions will occur in groups of 6-8 people with aphasia or with 2 people with aphasia. During treatment sessions, discourse will be facilitated on a focused set of every day topics, such as current events or travel. Linguistic and multi modal cueing hierarchies will be tailored to individual client goals and used to maximize communication success. The prediction is that conversation treatment is an effective method for improving communication in people with aphasia, but that specific benefits may differ based on variables such as group size, group composition, and aphasia severity. The results will help inform best practices for aphasia treatment and refine a hypothesized model about the mechanisms underlying conversation treatment.

Primary Outcome

The Aphasia Communication Outcome Measure (ACOM; Hula et al, 2015) is a patient reported outcome measure that reflects the clinical endpoint of conversation treatment. The ACOM is a psychometrically validated measure of the impact of aphasia on communication in daily life. The ACOM asks questions such as how effectively the person with aphasia talks to family members or clerks in a store. Standardized scores (T-scores) are computed, with higher values indicating better self-reported communicatio

Conditions Studied

Interventions

  • BEHAVIORAL Conversation Treatment for Aphasia

Study Locations (3)

Massachusetts

  • Boston University - Charles River Campus - Boston

New Jersey

  • Adler Aphasia Center - Maywood

Pennsylvania

  • Temple University - Philadelphia

Trial Details

FieldValue
Enrollment Target 162 participants
Start Date 2022-04-15
Est. Completion 2026-04-30
Phase NA

What the registry record for NCT05113160 still lists

NCT05113160 is an interventional study that assigns participants to a tested intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap, above the 92-participant average among 8 other Aphasia, Acquired trials with a reported enrollment target (76% higher).

The record links to 1 condition, with Aphasia, Acquired appearing as the primary indexed condition, and to 1 intervention - of which Conversation Treatment for Aphasia is the first listed.

NCT05113160 reports a single indexed study location in Massachusetts, New Jersey, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05113160 about?

NCT05113160 is a clinical study titled "Conversation Group Treatment for Aphasia: Does it Work?". The proposed research will test the efficacy of group conversation treatment for people with aphasia and explore whether the effects of treatment differ as a result of the following factors: 1. Group size: Do large groups of 6-8 people with aphasia or dyads of 2 people with aphasia demonstrate diff...

What is the current status of trial NCT05113160?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 162 participants. The study started on 2022-04-15. Estimated completion is 2026-04-30.

What conditions does trial NCT05113160 study?

This clinical trial studies the following conditions: Aphasia, Acquired.

What interventions are being tested in trial NCT05113160?

The interventions under investigation include: Conversation Treatment for Aphasia (BEHAVIORAL).

Who is sponsoring clinical trial NCT05113160?

This trial is sponsored by Boston University Charles River Campus, which has 104 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05113160 being conducted?

This trial has 3 study locations across Massachusetts, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aphasia, Acquired

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05113160's enrollment target sits among peer trials

162 2nd of 8 the highest of 8 other Aphasia, Acquired trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Aphasia, Acquired trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02347111 · 162 participants · Phase 4

    Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

  • NCT02610426 · 162 participants

    Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer

  • NCT05040711 · 162 participants · NA

    mHealth Mindfulness With Patients With Serious Illness and Their Caregivers

  • NCT05514717 · 162 participants · Phase 1

    A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05113160, the US trial registry maintained by the National Library of Medicine. NCT05113160 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.